A study to investigate the efficacy and safety of TRIV-509 compared with placebo in adults with moderate to severe atopic dermatitis

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Triveni Bio Inc.

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Diseases [C] - Skin and Connective Tissue Diseases [C17]

Trial duration

7 Jan 2026 → ongoing

Decision date (initial)

2025-12-10

Transition trial

No

Low-intervention

No

Rare-disease indication

No

Vulnerable population

Yes

Funding sources

Triveni Bio, Inc

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Pharmacokinetic, Efficacy, Safety, Pharmacogenomic

To assess the efficacy of TRIV-509 administered by SC injection for 12 weeks in adults with moderate to severe AD

Secondary objectives 1

1. 1. To further assess the efficacy of TRIV-509 administered by SC injection for 12 weeks in adults with moderate to severe AD. 2. To assess the safety and tolerability of TRIV-509 administered by SC injection every 4 weeks for a total of 12 weeks in adults with moderate to severe AD. 3. To assess the pharmacokinetics of TRIV-509 administered by SC injection every 4 weeks for a total of 12 weeks in adults with moderate to severe AD. 4. To assess the immunogenicity of TRIV-509 administered by SC injection every4 weeks for a total of 12 weeks in adults with moderate to severe AD.

Conditions and MedDRA coding

Atopic dermatitis

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 4

1. 1. Aged ≥ 18 to ≤75 years, inclusive, at the time of signing the informed consent. 2. Has chronic AD 3. Has had no significant flares in AD for at least 28 days prior to Screening, in the opinion of the Investigator. 4. Has moderate to severe, active, and symptomatic AD 5. Meets Pruritus NRS severity score requirements at baseline. 6. Has required systemic therapy to achieve adequate control of AD OR cannot use topical medications OR has a history of inadequate response to topical medications for at least 28 days, as judged by the Investigator. 7. Body weight ≥ 40 kg (88.2 pounds) at Screening
2. 8. A participant is eligible to participate if not pregnant or breastfeeding, and one of the following conditions applies: a. Is of nonchildbearing potential (NCBP) as defined in Appendix 4: Contraceptive and Barrier Guidance. OR b. Is of childbearing potential (CBP) and has a negative serum pregnancy test at Screening and a negative urine pregnancy test before the first dose of study intervention on Day 1 AND must agree to use a contraceptive method that is highly effective (with a failure rate of < 1% per year), preferably with low user dependency, as described in Appendix 4: Contraceptive and Barrier Guidance until EOS or for at least 24 weeks after the last dose of study intervention, whichever is later. Note: If the form of contraception used is a hormonal contraceptive, the participant must be on a stable dose of the hormonal contraceptive from weeks before Day 1 until the EOS or for at least 24 weeks after the last study intervention administration, whichever is longer. AND agrees not to donate ova until the EOS or for at least 24 weeks after the last dose of study intervention, whichever is later.
3. 9. Male participants of reproductive potential must a. refrain from donating sperm or fathering a child from Day 1 (first dose of study intervention) until at least 24 weeks after the last study intervention administration, AND b. must agree to use an additional highly effective contraceptive method with a failure rate of <1% per year, preferably with low user dependency, as described in Appendix 4: Contraceptive and Barrier Guidance, when having sexual intercourse with a partner of CBP until EOS or for at least 24 weeks after the last dose of study intervention, whichever is later. Note: If the female partner of a male participant uses any hormonal contraceptive, the female partner must be on a stable dose of hormonal contraceptive for ≥4 weeks before Day 1 until EOS or for at least 24 weeks after the last study intervention administration, whichever is longer.
4. 10. Signed informed consent as described in Section 10.1.3, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. 11. Willing to apply a stable dose of topical emollient throughout the study. 12. If currently receiving concomitant medications for any reason other than AD, is on a stable dose defined as not starting a new drug, changing, or stopping dosage within 7 days or 5 half-lives (whichever is longer) before Day 1 and through the treatment duration of the study. 13. Has not had excessive sun exposure, is not planning a trip to a sunny climate, has not used tanning booths within 28 days before Day 1, and is willing to minimize natural and artificial sunlight exposure during the study and to not use tanning booths, sun lamps or other ultraviolet light sources during the study.

Exclusion criteria 5

1. 1. Severe or uncontrolled medical conditions (including but not limited to cardiovascular, respiratory, endocrine, neurologic, immunologic, or psychiatric disease) that would put the participant at undue risk for participation in a clinical trial or compromise clinical trial interpretation. 2. History of cancer or lymphoproliferative disease within 5 years before Day 1. Participants with successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix remain eligible. 3. Had a major surgery within 8 weeks before Screening or has a major surgery planned during the study. 4. Evidence of an active and/or concurrent dermatologic condition (e.g., seborrheic dermatitis, psoriasis, acute allergic contact dermatitis) that would interfere with the Investigator or participant-driven evaluations of AD. 5. Active chronic or acute infection that requires treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 14 days before Day 1, or superficial skin infection (if requiring topical or systemic antibiotics) within 14 days before Day 1.
2. 6. History of active tuberculosis (TB), positive QuantiFERON-Gold TB test, or two indeterminate QuantiFERON-Gold TB tests. If the participant has a history of latent TB and/or positive QuantiFERON-Gold TB test but no history of active TB or signs/symptoms consistent with active TB with a regiment and duration consistent with country-specific guidelines before Screening, the participant remains eligible. If the first QuantiFERON-Gold TB test is indeterminant but the second is negative, the participant remains eligible. 7. Positive human immunodeficiency virus (HIV) antibody test. 8. Positive hepatitis B surface antigen (HBsAg) OR hepatitis B core antibody (anti-Hbc) test; for positive hepatitis B core antibody only, if reflex hepatitis B surface antibody (anti-Hbs) is positive AND hepatitis B DNA PCR is negative, participant remains eligible. Refer to Section 10.5 for additional guidance on hepatitis B testing. 9. Positive hepatitis C antibody test result with reflex positive HCV RNA at Screening. Note: For participants previously treated for hepatitis C, treatment must have been completed at least 84 days prior to Screening, with negative HCV RNA documented at that time and no positive RNA results thereafter. 10. Alcohol use disorder or substance use disorder within the past 12 months.
3. 11. Participant has a laboratory test result at Screening that would put the participant at undue risk for participation in a clinical trial or compromise clinical trial interpretation. 12. Known chronic liver disease, or elevations of AST or ALT ≥2× ULN, or total bilirubin 1.5× ULN at Screening. Participants with known Gilbert syndrome with persistent but otherwise not clinically significant elevations in total bilirubin remain eligible. 13. Use of topical treatments that could affect AD presentation or that could affect the assessment of AD (e.g., prescription moisturizers, moisturizers containing additives such as ceramide, hyaluronic acid, urea, or filaggrin; calcineurin inhibitors, tars, antibiotic creams, PDE-4 inhibitors, topical antihistamines, corticosteroids, bleach baths, and medical devices) within 14 days before Day 1. 14. Received phototherapy narrowband NB-UVB, broad-band phototherapy, psoralen-UV-A, or excimer laser within 28 days before Day 1. 15. Treatment with systemic immunosuppressive or immunomodulatory therapy that could affect AD (e.g., azathioprine, cyclosporine, systemic corticosteroids, Janus kinase inhibitors, methotrexate, mycophenolate-mofetil) within 28 days before Day 1.
4. 16. Treatment with immunomodulatory biologics as follows: • Dupilumab or other biologic targeting IL-13 or IL-4Ra within 90 days before Day 1. • Cell-depleting biologics, including rituximab, within 180 days before Day 1. 17. Other marketed or investigational immunomodulatory biologics within 5 half-lives (if known) or 112 days before Day 1, whichever is longer. 18. Treatment with oral antihistamines for AD within 7 days before Day 1. Note: A daily oral antihistamine for non-AD symptoms (e.g., allergies) is permitted if the dose is stable for at least 14 days before Day 1 and plans to continue to use the same agent at the same dose through the EOS/EOT visit. 19. Currently receiving a nonbiological investigational product or device or has received one within 5 half-lives of the drug or 28 days (whichever is longer) before Day 1.
5. Only for Participants Consenting to Biopsy Collection 20. History of an allergic reaction or significant sensitivity to lidocaine or other local anesthetics. 21. History of hypertrophic scarring or keloid formation in scars or suture sites. 22. Has taken anticoagulant medication, such as heparin, low molecular weight (LMW)‑heparin, warfarin, antiplatelets, within 14 days before Day 1, or has a contraindication to skin biopsies. Note: Nonsteroidal anti-inflammatory drugs (NSAIDs) will not be considered antiplatelets and will be allowed.

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

1. 1. Percentage of participants with improvement of AD at Week 16

Secondary endpoints 1

1. 1. Percentage of participants with improvement of AD at Week 16 5. Percentage of participants with TEAEs 6. Percentage of participants with SAEs 7. Changes in vital signs, ECG parameters, and safety laboratory values 8. Single-dose and multiple-dose PK parameters 9. Percentage of participants with anti-TRIV-509 antibodies

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 1

Placebo 1

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Triveni Bio Inc.

Sponsor organisation

Triveni Bio Inc.

Address

99 Coolidge Avenue Suite 450

City

Watertown

Postcode

02472-2802

Country

United States

Scientific contact point

Organisation

Triveni Bio Inc.

Contact name

Triveni Bio, Inc.

Public contact point

Organisation

Triveni Bio Inc.

Contact name

Triveni Bio, Inc.

Third parties 6

Locations

4 EU/EEA countries · 25 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 69 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

5 submissions — initial application plus substantial / non-substantial modifications